Therapy to Maintain Remission in Dilated Cardiomyopathy
Status:
Not yet recruiting
Trial end date:
2026-09-15
Target enrollment:
Participant gender:
Summary
One third of patients diagnosed with heart failure demonstrate left ventricular reverse
remodelling and recovery of cardiac function following a period of medical therapy. The
TRED-HF trial investigated the impact of therapy withdrawal in this cohort and found that 40%
of patients relapsed within 6 months of stopping treatment. In this follow-on study, the
investigators will investigate the safety of therapy withdrawal of sodium cotransporter 2
inhibitors (SGLT2i) and mineralocorticord receptor anatagonists (MRAs) in patients with a
previous diagnosis of heart failure and recovered cardiac function, in a randomised
controlled trial to assess whether this maintains remission in this population.